Category Archives: Regenerative Medicine

Chandler, AZ The focus on healthy living has increased the uptake of sports and other physical activities. However, this comes with an increased incidence of injuries. Traditional methods of managing these pains often involve drugs that may have adverse effects. However, there are safer and more effective alternatives, such as regenerative medicine. Regenerative medicine is a branch of medicine that focuses on the repair and regeneration of tissues. This treatment has shown great promise in treating various conditions, including joint pain, knee pain, back pain, and muscle pain. QC Kinetix (Chandler) is a leading provider of regenerative medicine in Arizona. The pain control clinic has seasoned treatment providers passionate about helping their patients live their best lives.

A healthy back is vital to a persons quality of life. It allows us to do the things we love without pain or worry. When our backs are injured, it can be difficult to return to normal activities. Our team at QC Kinetix (Chandler) is dedicated to helping patients find relief from back pain and regain their quality of life. To learn more about their Chandler office, please visit their website.

Any physical exertion strains the joints, which can result in pain and inflammation. In some cases, the damage to the joints may be too extensive for them to heal independently. Regenerative medicine can help to repair this damage and promote healing. This minimally invasive treatment option is a great alternative to traditional methods, such as surgery, and the Chandler joint pain treatment clinic has set the pace in providing this treatment to patients in Arizona. Their customized approach to each patients condition ensures they get the best possible results.

The knees are some of the most vulnerable joints in the body that are susceptible to injury and pain, and for athletes, knee pain can be a career-ending injury. However, biologic therapies have shown great promise in treating knee injuries. These therapies use the bodys own healing mechanisms to repair the damage. QC Kinetix (Chandler) offers customized biologic therapy treatments designed to enhance the healing process.

The ability to move the arms freely is often taken for granted. However, this movement may be restricted by shoulder pain. The shoulder is a complex joint that is made up of bones, muscles, and tendons, and any injury to these structures can result in pain. For instance, rotator cuff tears commonly cause shoulder pain among athletes. However, this condition can be effectively treated with biologic therapies. The benefit of these therapies is their short recovery time, as biologic therapies help promote the bodys natural healing process. QC Kinetix (Chandler) is one of the clinics steering the way in providing these restorative therapies to patients.

QC Kinetix (Chandler) is located at 1100 S Dobson Rd, Suite 210, Chandler, AZ, 85286, US. Clients can also contact the pain control clinic at (602) 837-7246. They can also learn more by browsing the companys website.

Media Contact

Company NameQC Kinetix (Chandler)Contact NameScott HootsPhone(602) 837-7246Address1100 S Dobson Rd, Suite 210CityChandlerStateAZPostal Code85286CountryUnited StatesWebsitehttps://qckinetix.com/phoenix/chandler/

See the article here:
QC Kinetix (Chandler): The Future of Regenerative Medicine in Arizona - Digital Journal

Platelet-rich plasma (PRP) could be understood as a special preparation of plasma in which the concentration of platelet is immensely high. This rationale for plasma use hasbeen in the medical sciencefor many years with plenty of success in various fields where it was inculcated, bringing dramatically favorable and better outcomes in terms of disease management and prognosis. PRP has been widely used in orthopedics from the very beginning, but in the past few years its use has been extended to other fields too, such as obstetrics and gynecology. From the very onset of the introduction of platelet-rich plasma in gynecology, there had been constant researchbeing carried out all around the globe in order to scientifically prove and confirm its exact role in the management of gynecologicalproblems. Regenerative medicine in gynecologywas among the first areas where the platelet-rich plasma was implemented and has substantially given great results, which encouraged further extensiveresearchto be carried out in other spectrums of gynecology.The implications of such great struggles ultimately gave way to evidencesuggesting the importance of platelet-rich plasma in managing gynecological disorders like Ashermans syndrome, urinary incontinence, genital fistulas, thin endometrium, etc. This review article collectively summarizes the various use of platelet-rich plasma in gynecology.

Platelet-rich plasma (PRP) may be understood as an autologous plasma preparation that is enriched with an increased concentration of platelet when compared to those present in whole blood [1]. The immense potential of platelet-rich plasma is often not made use of, as this particular entity is seldom understood in depth as it should be. Researchis being conducted all around the globe to understand the true potential of platelet-rich plasma, and undoubtedly a deeper knowledge of the same could be a solution to many problems in medical science, as this would pave the way for advanced and affordable therapeutic management strategies. Platelet-rich plasma (PRP) is obtained by the centrifugation of whole blood [2]. PRP contains growth factors and bioactive proteins that positively aid in the healing of ligament, bone, tendon and muscle [3]. It has been used in sports medicine to a good extent because of its effects on the musculoskeletal system. PRP has been helpful in tackling medical conditions in sports like muscle strains, Achilles tendon, lateral epicondylitis, ligament strains, rotator cuff tears, etc. [4].The incorporation of PRP into the hydrogel, which on biomineralization, could significantly accelerate the generation of bone [5]. In patients with androgenic alopecia, the use of PRP has the potential for hair restoration [6]. Apart from the increment in hair growth, the quality and density of the hair are also increased with its use [7]. It is also used in plastic facial surgeries because of its potential in the healing of wounds [8]. PRP, when combined with autologous fat grafting, laser therapies, dermal fillers, and microneedling, have been found to have synergistic effects that lead to better aesthetic outcomes apart from their widespread applications in dermatology like the areas of acne scars, striae distensae, skin rejuvenation, dermal augmentation, hair restoration, etc. [9]. PRP is a potential candidate for the regeneration of damaged tissues, including the liver and the dental pulp [10]. Autologous PRP could be developed easily and is an effective surgical adjunct, which is proven to be helpful in accelerating postsurgical healing in oral surgeries and periodontics [11]. The extensive use of the platelet-rich plasma in gynecology is hopefully expected to give good positive results, as was seen in musculoskeletal system and skin regeneration.

The abundant use of PRP in regenerative medicine has provoked researchers all around the world to apply its potential in other fields of medical science too. These efforts were carried out in obstetrics and gynecology as well, and the outcome was a wide range of applications in the domain of reproductive medicine, particularly in Ashermans syndrome, cases of thin endometrium, urinary incontinence, recurrent genitourinary fistula auxiliary treatment, etc.[12]. Although this requires more research, with the little information that is available now from the few research conducted, there is a good hope that in the near future, platelet-rich plasma could resolve various challenges that are currently being faced in obstetrics and gynecology. Some of its achievements in gynecologyand obstetrics are a decrease in the FSH levels, increasedendometrial thickness, increasedanti-Mullerian hormone (AMH), etc. [13]. If the potential of PRP is utilized, then women who suffer from premature ovarian insufficiencies, poor ovarian reserve, and even early menopause cases where they are trying to conceive using their own oocytes may find this helpful [14]. The benefits of the use of PRP over conventional management strategies in obstetrics and gynecology include minimally invasive procedures, low cost, easy availability, lesser adverse effects, etc., but the issue that is quite prominent is that there is as such, no standardized concentration of PRP that could effectively resolve gynecological problems in one go. PRP is concerned that they shouldnt be used in coagulation disorder patients [15]. The use of platelet-rich plasma in patients with coagulation disorders would worsen their general condition at a very rapid pace, thus, should neverbe used in these patients. There are other conditions too, where it is prudent to avoid its use as a management modality, such as cases of active infectionsor patients under NSAIDs; particularly with respect to gynecology, it should never be prescribed to pregnant women and lactating mothers [16]. Stress urinary incontinence and overactive bladder are two gynecological entities that affecta vast majority of women, and the good part is that treatment with PRP had a profound impact on these disorders [12].

Although platelet-rich plasma (PRP) therapies have a huge potential to revolutionize the management of various gynecological conditions at this point in time, only a very less fraction of the same is made a reality. The continuing research in the field of gynecologyhas hope for the involvement of more of this gracious and effective management strategyand, for the time being, more research is to be conducted to deepen the understanding of the effects of PRPon thediseases it is being tried out. Here, in this review article, some of the widely promising and practically applicable aspects of the gynecological manifestations would be dealt with.

An intact endometrium is one of the main prerequisites for the implantation to take place. Much of the implantation-related pregnancy issues do take place as a result of the disparities in the endometrial layer. A proper endometrium is a must for safe implantation. Platelet-rich plasma interventions have been shown to successfully figure out several issues of the endometrium and thus haveproved beneficial to many women suffering from endometrial problems. Platelet-rich plasma increased the receptivity of the endometrium and thereby ledto a rise in the rate of implantation. In patients with thin endometrium, platelet-rich plasma is effective in the growth of endometrium as it restores the structure of the endometrium and decreases fibrosis. Their role in the management of Ashermans syndrome is also phenomenal. It aids in the management of patients with endometrial difficulties that are a result of associated chronic systemic diseases and thus has emerged as a golden ray of hope even in these low prognosis patients. Various studies have proved its effectiveness in endometrial abnormalities [17-20] (Table 1).

Platelet-rich plasma (PRP) has promising positive impacts on the growth of follicles alongside endometriumand thus has become a good alternative for older womenwho possess low follicular reserve and unresponsive endometriumseeking motherhood [21]. The improvement in the microenvironment of ovaries, along with the provision of growth factors for germline stem cells of the ovaries makes platelet-rich plasma a potential management strategy for low reserves of the ovaries [22]. The injection (intra-ovarian) of calcium gluconate-activated autologous platelet-rich plasma is likely to improve the functions of the ovaries after a span of two months in 38 to 46 years age group women [23]. The advantage of the ovaries being amassively angiogenic organ is that it could be expected that neoangiogenesis in ovarian tissues could be brought about by angiogenic factors that are derived from the platelet-rich plasma, which, in turn, makes room for the reactivation and regeneration of tissue [24].

In the autologous transplantation of ovaries, the angiogenicpotential of platelet-rich plasma is made handy [25]. Damages to the ovaries that occuras a result of torsion-related ischemia would be reduced to a good extent by the administration of platelet-rich plasma intraperitoneally [26]. Oxidative stress-induced injuries are prevented with the help of platelet-rich plasma as it increases vascular endothelial growth factor (VEGF) and a few nuclear factors that aid in angiogenesis [27]. Even though platelet-rich plasma is made useful in various ovary-related problems but more researchwould help add more gynecological problems to the list that PRP could resolve. Platelet-rich plasma is serving as a good management strategy in tackling many of the urinary problems of patients attending gynecology clinics. It has a profound effect as a supportive treatment modality in case of recurrent vesicovaginal fistulas. Disorders of the urinary tract and difficulty in urination were seldom complained by patients in whom platelet-rich plasma was used asadjuvant therapy for the treatment of recurrent vesicovaginal fistula [28]. PRP is also found to be of use in the management of cystoceles. Considering the complications of cystoceles like mesh complications, platelet-rich plasma may serve as a good option to prevent the recurrence of cystoceles [29].

Platelet-rich plasma is useful in cases of stress urinary incontinence (SUI) as PRP contains several growth factors that helpin the reconstruction of the damaged ligament in, i.e., pubourethral ligament [30]. Urethral sphincter injection of platelet-rich plasma is a minimally invasive, safe, and effective treatment modality in cases of postprostatectomy urinary incontinence with considerable urodynamic and clinical evidence[31]. Platelet-rich plasma helps not only in the management of urogynaecological problems but is handy in the diagnosis of certain conditions like painful bladder syndrome/interstitial cystitis. It has the potential to act as a modulatorof urothelial repair,and this could be made useful in painful bladder syndromes [32]. Various researchin the past couple of years is clearly suggestive of the fact that intravesical platelet-rich plasma reduces chronic inflammation in bladder pain syndrome/interstitial cystitis (BPS/IC) as they could improve regeneration of the urothelium [33].

There is clinical evidencethat the injections of platelet-rich plasma could substantially decrease the urinary inflammatory proteins in interstitial cystitis/bladder pain syndrome (IC/BPS) and thus aids in the improvement of symptoms [34]. A study demonstrated that autologous platelet-rich plasma intravesical injections helped to improve interstitial cystitis as it safely decreases MMP-13, urinary NGF, and levels of VEGF [35]. The instillation of intravesical PRP has been found to increase the mitotic index in cyclophosphamide and saline groups, along with aiding in the decrement of bleeding macroscopically [36]. Considering the outcomes of multiple types of research, we could come to an inference that the intravesical injection of platelet-rich plasma could potentially act as an effective and safe treatment option in cases of bladder pain syndrome by its multiple actions that aidin tissue regeneration, wound healing and modulation of the immunity [37].

After having a careful review of the various research works on the use of platelet-rich plasma in gynecology, published on internationally recognized scientific platforms, various valuableinsights were obtained, which havethe potential to bring about a great revolution in obstetrics and gynecology. Starting from very minor ailments and spanning to some of the most chronic forms of gynecological issues, platelet-rich plasma is undoubtedly a worthy candidate for the management of these problems. The wide spectrum of its usage has made various gynecological issues such as thin endometrium, recurrent genital fistulas, ovarian abnormalities, Ashermans syndrome, urinary stress incontinence, etc., effectively managed. Platelet-rich plasma has been scientifically proven to increase the thickness of the endometrium. Therebyaiding implantation in women as implantation wouldnt have been otherwise possible in these females because of their thin endometrium. Those women who were suffering from ovary-related issues benefited when platelet-rich plasma was administered to them. The role of platelet-rich plasma in the management of urinary complaints is phenomenal, and thus the implementation of PRP substantially improves the symptoms in these women. From the analysis of the effects of platelet-rich plasma in gynecology which is currently available, there is no doubt that more research would aid in discovering the hidden potentials of platelet-rich plasma in the management of many more of the issues encountered in gynecology.

The rest is here:
Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders - Cureus

Today, the White House will host a Summit on Biotechnology and Biomanufacturing. The Summit is led by National Security Advisor Jake Sullivan, Director of the National Economic Council Brian Deese, and Director of the Office of Science and Technology Dr. Alondra Nelson who will be joined by Secretary of Health and Human Services Xavier Becerra, Secretary of Energy Jennifer Granholm, Deputy Secretary of Defense Kathleen Hicks, Deputy Secretary of Agriculture Jewel Bronaugh, Under Secretary of Commerce for Standards and Technology and Director of the National Institute for Standards and Technology Laurie Locascio, and Director of the National Science Foundation Sethuraman Panchanathan, as well as Senator Mark Warner and Representative Deborah Ross. Together, they will lift up the following key stepswith funding of more than $2 billionto advance President Bidens Executive Order to launch a National Biotechnology and Biomanufacturing Initiative to lower prices, create good jobs, strengthen supply chains, improve health outcomes, and reduce carbon emissions. U.S.departments and agencies will:Leverage biotechnology for strengthened supply chains. The Department of Health and Human Services will invest $40 million to expand the role of biomanufacturing for active pharmaceutical ingredients (APIs), antibiotics, and the key starting materials needed to produce essential medications and respond to pandemics. DoD is launching the Tri-Service Biotechnology for a Resilient Supply Chain program with more than $270 million investment over five years to turn research into products more quickly and to support the advanced development of bio-based materials for defense supply chains, such as fuels, fire-resistant composites, polymers and resins, and protective materials. Through the Sustainable Aviation Fuel Grand Challenge, the Department of Energy (DOE) will work with the Department of Transportation and USDA to leverage the estimated 1 billion tons of sustainable biomass and waste resources in the United States to provide domestic supply chains for fuels, chemicals, and materials. These efforts will collectively lower prices for American families, especially in times of global supply chain turbulence.Expand domestic biomanufacturing. The Department of Defense (DoD) will invest $1 billion in bioindustrial domestic manufacturing infrastructure over 5 years to catalyze the establishment of the domestic bioindustrial manufacturing base that is accessible to U.S. innovators. This support will provide incentives for private- and public-sector partners to expand manufacturing capacity for products important to both commercial and defense supply chains, such as critical chemicals. DoD will invest an additional $200 million to support enhancements to biosecurity and cybersecurity posture for these facilities. The U.S. Department of Agriculture (USDA) will make $500 million available through a new grant program in the summer of 2022 to support independent, innovative, and sustainable American fertilizer production to supply American farmers, which can make use of advances in biotechnology and biomanufacturing.Foster innovation across the United States. The National Science Foundation (NSF) recently announced a competition to fund Regional Innovation Engines throughout the United States. These Engines will support key areas of national interest and economic promise, including biotechnology and biomanufacturing topics such as manufacturing life-saving medicines, reducing waste, and mitigating climate change. In May 2022, USDA announced $32 million for wood innovation and community wood grants, leveraging an additional $93 million in partner funds to develop new wood products and enable effective use of U.S. forest resources. DOE also plans to announce new awards of approximately $178 million to advance innovative research efforts in biotechnology, bioproducts, and biomaterials. In addition, the U.S. Economic Development Administrations $1 billion Build Back Better Regional Challenge will invest more than $200 million to strengthen Americas bioeconomy. Investments in New Hampshire, Virginia, North Carolina, Oregon, and Alaska will help expand the bioeconomy by advancing regional biotechnology and biomanufacturing programs. These regional investments will rebuild pharmaceutical supply chains to lower drug costs, catalyze a sustainable mariculture industry, better utilize mass timber to accelerate affordable housing production and restore forest health, enhance the production and distribution of regenerative tissues and organs, and develop a robust pipeline of biotech talent, expanding opportunities to underserved and historically excluded communities.

Bring bio-products to market. DOE will provide up to $100 million for research and development (R&D) for conversion of biomass to fuels and chemicals, including R&D for improved production and recycling of biobased plastics. DOE will also double efforts, adding an additional $60 million, to de-risk the scale up of biotechnology and biomanufacturing that will lead to commercialization of biorefineries that produce renewable chemicals and fuels that significantly reduce greenhouse gas emissions from transportation, industry, and agriculture. USDAs BioPreferred Program advances the development and expansion of markets for biobased products with a catalog of over 16,000 registered products. The new $10 million Bioproduct Pilot Program will support scale-up activities and studies on the benefits of biobased products. Manufacturing USA institutes BioFabUSA and BioMADE (launched by the DoD) and NIIMBL (launched by the Department of Commerce (DOC)) will expand their industry partnerships to enable commercialization across regenerative medicine, industrial biomanufacturing, and biopharmaceuticals. For example, NIIMBL will launch a biomanufacturing initiative that will engage the institutes 200 partners across industry, academic, non-profit, and Federal agencies to mature biomanufacturing technology needed to improve patient access to gene therapies. BioMADE will launch hubs supporting equitable regional development, create jobs nationwide, and enhance American economic competitiveness. BioFabUSA is standing up the BioFab Foundries, a first-of-its-kind U.S. facility that integrates engineering, automation, and computation with biology. BioFab Foundries will be accessible to U.S. innovators to enable manufacturing of preclinical and early-stage clinical products.Train the next-generation of biotechnologists. The National Institutes of Health (NIH) is expanding the I-Corps program, a biotech entrepreneurship bootcamp. NIIMBL will continue to offer a summer immersion program, the NIIMBL eXperience, in partnership with the National Society for Black Engineers, that connects underrepresented students with biopharmaceutical companies, and support pathways to careers in biotechnology. In March 2022, USDA announced $68 million through the Agriculture and Food Research Initiative to train the next generation of research and education, professionals.Drive regulatory innovation to increase access to products of biotechnology. The Food and Drug Administration is spearheading efforts to support advanced manufacturing through regulatory science, technical guidance and increased engagement with industry seeking to leverage these emerging technologies These efforts will increase medical supply chain resilience and improve patient access to new medical products. NIHs Accelerating Medicines Partnership Bespoke Gene Therapy Consortium will support up to six new clinical trials, each focused on a different rare disease, to streamline manufacturing and regulatory frameworks. For agricultural biotechnologies, USDA is building new regulatory processes to promote safe innovation in agriculture and alternative foods, allowing USDA to review more diverse products.Advance measurements and standards for the bioeconomy. DOC plans to invest an additional $14 million next year at the National Institute of Standards and Technology for biotechnology research programs to develop measurement technologies, standards, and data for the U.S. bioeconomy. This support will catalyze development of capabilities for engineering biology, advance biomanufacturing processes and technologies, and help utilize artificial intelligence to analyze biological data.Reduce risk through investing in biosecurity innovations. DOEs National Nuclear Security Administration plans to initiate a new $20 million bioassurance program that will advance U.S. capabilities to anticipate, assess, detect, and mitigate biotechnology and biomanufacturing risks, and will integrate biosecurity into biotechnology development.Facilitate data sharing to advance the bioeconomy. Through the Cancer Moonshot, NIH is expanding the Cancer Research Data Ecosystem, a national data infrastructure that encourages data sharing to support cancer care for individual patients and enables discovery of new treatments. USDA is working with NIH to ensure that data on persistent poverty can be integrated with cancer surveillance. NSF recently announced a competition for a new $20 million biosciences data center to increase our understanding of living systems at small scales, which will produce new biotechnology designs to make products in agriculture, medicine and health, and materials.

###

Read the rest here:
FACT SHEET: The United States Announces New Investments and Resources to Advance President Bidens National Biotechnology and Biomanufacturing...

LEXINGTON, Ky. (WTVQ) Four will be inducted into the Equine Research Hall of Fame, the University of Kentucky Gluck Equine Research Center announced Wednesday.

The induction honors achievements in equine research and those who have made a lasting tribute to equine health. The induction will be held on Wednesday, Oct. 26 at Kroger Field for Lisa Fortier, Katrin Hinrichs, Jennifer Anne Mumford and Stephen M. Reed.

The following achievements were provided via a press release:

Lisa Fortier

Over the past 30 years, Fortier has garnered an international reputation for significant contributions in equine joint disease, cartilage biology and regenerative medicine. She has focused her research on early diagnosis and treatment of equine orthopedic injuries to prevent permanent damage to joints and tendons. She is perhaps best known for her work in regenerative medicine, pioneering the use of biologics such as platelet-rich plasma, bone marrow concentrate and stem cells for use in horses and humans. Fortiers lab has also been instrumental in breakthroughs related to cartilage damage diagnosis and clinical orthopedic work. A testament to her impact is that 87% of U.S. equine veterinarians now use biologics for regenerative medicine in their equine patients.

Fortier earned her bachelors degree and doctor of veterinary medicine degree from Colorado State University. She completed her residency at Cornell, where she also earned a Ph.D. and was a postdoctoral fellow in pharmacology. She now holds the James Law Professor of Surgery position at Cornells College of Veterinary Medicine. She is the editor-in-chief of the Journal of the American Veterinary Medical Association and serves on the Horseracing Integrity and Safety Authority Racetrack Safety Standing Committee.

Katrin Hinrichs

Hinrichs devotes her career to research primarily in equine reproductive physiology and assisted reproduction techniques. Specifically, her focus has included equine endocrinology, oocyte maturation, fertilization, sperm capacitation and their application to assisted reproduction techniques.

Hinrichs 40 years of research have led to several significant basic and applied research achievements. The applied accomplishments include producing the first cloned horse in North America and developing the medical standard for effective intracytoplasmic sperm injection and in vitro culture for embryo production in horses. She has mentored more than 85 veterinary students, residents, graduate students and postdoctoral fellows in basic and applied veterinary research. Her laboratories have hosted approximately 50 visiting scholars from throughout the world.

Hinrichs earned her bachelors degree and doctor of veterinary medicine degree from the University of California, Davis. She completed residency training in large animal reproduction at the University of Pennsylvanias New Bolton Center and earned a Ph.D. at the University of Pennsylvania.

Jennifer Anne Mumford

A posthumous inductee, Mumford earned international respect as one of the most prominent researchers of equine infectious diseases, in particular equine viral diseases. Her distinguished career at the Animal Health Trust, Newmarket, United Kingdom, began when she became the first head of the newly established equine virology unit. Her work focused on the leading causes of acute infectious respiratory disease in the horse, primarily equine herpesvirus and equine influenza virus, and to a lesser extent,Streptococcus equi, the causative agent of equine strangles.

Mumford made numerous significant contributions in these areas, including developing improved vaccines, diagnostics and international surveillance. She also helped establish research groups in the related fields of equine genetics and immunology.

During Mumfords more than 30 year-career, she established the Animal Health Trust as one of the worlds leading centers for the study of the biology, epidemiology, immunology and pathology of diseases, including equine herpes rhinopneumonitis and equine influenza, as well as bacterial diseases, including Streptococcus and Clostridium.

Stephen M. Reed

Reeds nominators credited him as the last word in equine neurology. Reed is widely recognized as one of the most prominent equine neurologists worldwide. His list of 180 peer-reviewed publications includes significant contributions to equine medicine, neurology, physiology and pathophysiology, and has earned him worldwide recognition throughout the equine community. He has shared in his achievements as a mentor and role-model for hundreds of aspiring equine practitioners.

One of the most unique and refreshing things about Dr. Reed is he absolutely embodies the need and overlap of discovery science with clinical assessments to further our understanding of equine neurologic disease, wrote Jennifer Janes, associate professor of veterinary pathology at the UK Veterinary Diagnostic Laboratory, in her letter of support for the nomination. This mission has served as the foundation and pillars of his long career in equine veterinary medicine.

Reed earned his bachelors degree and doctor of veterinary medicine degree from The Ohio State University. He completed internship and residency training in large animal medicine at Michigan State University.

Read the rest here:
4 to be inducted into UK Equine Research Hall of Fame - WTVQ

AVITA Medical

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced positive topline results from a pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL System for repigmentation of stable vitiligo lesions.

The study compared repigmentation success rates, in a design where each patient randomly received RECELL treatment in one portion of depigmented area and treatment with the study control in another portion of depigmented area. The study control treatment was the standard of care narrowband ultraviolet-B phototherapy, which is typical first-line treatment for vitiligo. Repigmentation was evaluated 6 months after treatment by an expert central review committee (CRC).

The CRC reported the following:

Fifty-six percent (56%) of RECELL treatments (versus 12% of control treatments) resulted in repigmentation of more than 50% of the treated area

Thirty-six percent (36%) of RECELL treatments (versus 0% of control treatments) resulted in repigmentation of at least 80% of the treated area, establishing super-superiority for the primary endpoint (p<0.025)

RECELLs compelling safety profile to date is reflected in preliminary review of adverse events in this study.

These are the first results from a U.S. randomized, controlled trial of the RECELL System in treating patients with segmental and nonsegmental stable vitiligo and provide a foundation for communicating favorable clinical benefit in pursuit of FDA approval via submission of a PMA supplement for this indication later this year.

Vitiligo often has a severe impact on quality of life and is a therapeutic area within which there have been very limited treatment options. We are excited by our topline data, as we are now closer to our goal of providing patients with a durable, clinically meaningful, one-time treatment for repigmentation, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. RECELL has the potential to address the unmet medical need for an estimated 1.3 million people in the U.S. who suffer from stable vitiligo, and further, we envision a potential opportunity for RECELL as part of a multi-modal treatment plan for patients achieving stability with JAK inhibitor treatment.

Story continues

Repigmentation is challenging to manage and burdensome for patients with vitiligo, said Iltefat Hamzavi, MD, of Henry Ford Hospital (Detroit, MI), lead investigator of the trial. These are encouraging results that underscore the potential for RECELL to address repigmentation in patients with stable vitiligo in a rapid and sustained fashion which is distinct from existing therapies.

Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including up to 6.5 million Americans,ii with an estimated 1.3 million suffering from stable vitiligo. Vitiligo has a comparable psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iii, iv, v Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.vi

ABOUT AVITA MEDICAL, INC.AVITAMedical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnessesthe regenerative properties of a patients own skin to create Spray-On Skin cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including acute traumatic wounds and repigmentation of stable vitiligo lesions.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 15,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, acute traumatic wounds, vitiligo, and aesthetics. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan. To learn more, visitwww.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

U.S. MediaSam Brown, Inc.Christy CurranPhone +1-615-414-8668christycurran@sambrown.com

O.U.S. MediaRudi Michelson Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au

InvestorsWestwicke PartnersCaroline CornerPhone +1-415-202-5678 caroline.corner@westwicke.com

i Picardo et al. Vitiligo. Nature Reviews Disease Primers. 2015.ii John Harris, MD, PhD Presentation as part of Incyte Corporate presentation. (Harris, UMass, is a global leader in Vitiligo; AVITA collaborator). https://investor.incyte.com/static-files/01f77a1c-6351-4348-adc2-597e2bc1f42eSERTiii National Psoriasis Foundation Statistics, https://www.psoriasis.org/psoriasis-statistics/ Accessed 10/5/2020iv The burden of vitiligo: Patient characteristics associated with quality of life. Homan, et al. JAAD. 2009v Comparison of the Psychological Impacts of Asymptomatic and Symptomatic Cutaneous Diseases: Vitiligo and Atopic Dermatitis.Noh, et al. Annals of Derm. 2013vi Willingness-to-pay and quality of life in patients with vitiligo. Radtke, et al. BJD. 2009

See the original post here:
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL System - Yahoo Finance

Life sciences company Carmell Therapeutics started September by taking the first steps toward going public: filing a draft registration statement with the US Securities and Exchange Commission for a public stock listing.

CEO and President Randy Hubbell told Technical.ly that taking the company public primes the Carmell Therapeutics products for commercialization. Currently in the clinical development stage, the South Side-based startup has investors, but no revenue. So when the company has finished with its clinical trials and been listed on the Nasdaq its aiming for Q4 2022 or early 2023 Hubbell says the company will be able to show the value of its products and positively impact future sales.

Why follow the 2021 steps of fellow Pittsburgh companies Duolingo, Stronghold Digital Mining, Aurora and Cognition Therapeutics and go public?

We believe that the better place to be is in the public markets where we can attract capital, because we look a lot like a biotech company, Hubbell said. Biotech companies have had success in the public markets by creating value for their investors by successfully advancing through the clinical regulatory pathway and bringing forth significant clinical data.

Randy Hubbell. (Courtesy photo)

The products Carmell Therapeutics would like to advance focus on regenerative medicine, including for tissue, hair, skin, bones after injury, disease or aging. Recently the company has completed Phase 2 of a study showing its Bone Healing Accelerant which has the ability to (as you might have guessed) accelerate and heal bone and soft tissue damage. The second product its been preparing is its Tissue Healing Accelerant which focuses on chronic wound healing and hair regrowth for individuals with alopecia.

All of those applications are very large total available markets, and all of them have significant unmet needs, Hubbell said. Our technology has promise of working to regrow those tissues because the base technology is very well understood and the science is very well known.

The Carnegie Mellon University spinout develops its technology by using allogeneic plasma, which contains significant growth factors and regenerative factors that are an important part of regrowing tissue. Hubbell explained that recently the company had obtained the Investigational New Drug clearance from the US Food and Drug Administration, meaning it has the green light to conduct clinical testing of the Bone Healing Accelerant. Additionally, the FDA has granted the companys technology an expedited review, a process meant to get important drugs to patients faster.

That suggests that they see that there is a significant unmet need without the necessary technology to address and they believe our technology would help meet that medical unmet need in tibia fractures, Hubbell said. What were doing is a big vision. It could fundamentally change the way tissue is healed and regrows after disease, injury and aging.

Carmell Therapeutics HQ. (Courtesy photo)

With plans to go public and clinical trials progressing, Hubbell said the company currently comprising 15 employees, nine of which are Pittsburgh based is set to expand by doubling its staff and possibly expanding its building to accommodate manufacturing when the time for commercialization comes. Still, even as the company grows larger with more researchers and finance staff, Hubbell insists Carmell Therapeutics is committed to continuing to call Pittsburgh home.

Were fully committed to Pittsburgh, were fully committed to the River Park Commons facility, the CEO said of Carmells HQ. We have no, no plans on leaving the Pittsburgh area or South Side.

Excerpt from:
Following some big FDA wins, Carmell Therapeutics plans to go public. Here's why - Technical.ly

Chicago, Sept. 13, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Cell Culture Media Market by Type(Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application(Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User(Pharma, Biotech) - Global Forecast to 2026", is projected to USD 10.3 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 16.0 % between 2021 and 2026.

Browse in-depth TOC on "Cell Culture Media Market"314 - Tables41 - Figures303 - Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97468536

The growth of this market is majorly driven by the rising R&D spending in pharmaceutical companies, emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. On the other hand, expensive cell biology research products and ethical concerns regarding cell biology research are expected to hinder the growth of this market.

Based on type, the cell culture media market is segmented intoserum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2020, the serum-free media segment accounted for the largest share of the market. This can be attributed to the advantages of serum-free media over other types of media, including consistent performance, increased growth & productivity, better control over physiological responsiveness, and reduced risk of contamination by serum-borne adventitious agents in cell culture.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=97468536

Based on application, the cell culture media market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is further divided into monoclonal antibody production, vaccine production, and other therapeutic protein production. The tissue engineering & regenerative medicine segment is further divided into cell & gene therapy and other tissue engineering & regenerative medicine applications.The biopharmaceutical production segment is estimated to grow at the highest rate during the forecast period. The high growth of this segment is attributed to the commercial expansion of major pharmaceutical and biotechnology companies, the increasing demand for mAbs, and the growing regulatory approvals for the production of cell culture-based vaccines.

Based on end user, the cell culture media market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and other end users (such as cell banks, CDMOs, and CROs). In 2020, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market. This end-user segment is also estimated to grow at the highest growth rate during the forecast period.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=97468536

Geographical Growth Scenario:

The global cell culture media market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to register the highest CAGR during the forecast period. The growing geriatric population, favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian economies are the major factors contributing to the growth of the market in the Asia Pacific.

Key Players:

Key players in the cell culture media market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany), Corning Incorporated (US).

Browse Adjacent Markets:Biotechnology Market Research Reports & Consulting

Browse Related Reports:

Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025

Cell Culture Market by Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) - Global Forecast to 2026

Read more from the original source:
Cell Culture Media Market worth $10.3 billion by 2026 - Exclusive Report by MarketsandMarkets - GlobeNewswire

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications.

Capstans foundational precision in vivo engineering technology builds on research conducted in the laboratories of world-renowned mRNA and cell therapy scientists at the University of Pennsylvania.

Capstans funding includes a recently closed $102 million Series A financing led by Pfizer Ventures and joined by Leaps by Bayer, Eli Lilly and Company, Bristol Myers Squibb, Polaris Partners, Alexandria Venture Investments, and all existing investors, which follows a $63 million seed financing led by Novartis Venture Fund and OrbiMed and joined by RA Capital, and Vida Ventures in November 2021.

Advancing Breakthrough Therapies through Precision in vivo Engineering

The company plans to use the funds to further its mission of advancing the clinical promise of cell-based therapies by enabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories. Capstans modular platform leverages the biological and technological expertise of its founding scientists and includes proprietary targeted lipid nanoparticles (tLNP) technology, a suite of targeting moieties to mediate cell type-specific uptake, and disease-specific mRNA payloads aimed at directly engineering, or ablating pathogenic cells through in vivo generated CAR T cells.

Capstan is prioritizing programs based on the potential to transform clinical standards of care. The companys initial efforts will focus on developing first-in-class in vivo CAR therapies, with the goal to deliver treatments in an outpatient setting, for patients who have diseases for which there are no effective treatments. Capstan also plans to leverage its precision delivery and engineering technology to advance new therapies for certain monogenic blood disorders.

Visionary Team of Accomplished Executives Poised to Deliver a Transformational Approach

Capstan is also pleased to announce that Laura Shawver, Ph.D., has joined the company as President and Chief Executive Officer. Dr. Shawver brings more than 20 years of experience in executive leadership positions in oncology and other serious diseases to this role, most recently serving as CEO of Silverback Therapeutics and President and CEO of Synthorx.

Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells, said Dr. Shawver. Our founding scientific and operational team is purpose-built to advance programs to the clinic that unite decades of combined experience in groundbreaking CAR therapies with the latest advances in mRNA delivery technology. We are also fortunate to have a distinguished investor syndicate that understands the cell therapy landscape and recognizes the potential of this innovative approach. I am thrilled to lead this team as we work toward making this vision a reality for patients.

Laura is an exceptional leader with a well-established track record in drug development and passion for addressing unmet needs in oncology and other serious diseases, said Michael Baran, Ph.D., Partner, Pfizer Ventures. We are delighted to have someone of Lauras caliber captain this exciting next chapter for Capstan to help unlock the potential of this transformative approach for patients.

Dr. Shawver joins an accomplished leadership team of industry veterans who have been at the forefront of cell and gene therapy, including Adrian Bot, M.D., Ph.D., Chief Scientific Officer, formerly Global Head and Vice President of Translational Medicine at Kite, a Gilead Company and previously Chief Scientific Officer at Kite Pharma; and Priya Karmali, Ph.D., Chief Technology Officer, who has over two decades of experience in the field of lipid nanoparticle mediated nucleic acid delivery technologies.

Building on Pioneering Work of World-Renowned Scientific Founders

Capstan builds on a deep history of collaborative research in mRNA-enabled and CAR-based medicines by our incredible group of scientific founders, said Christian Homsy, M.D., MBA, Capstans founding CEO. The company was established to deliver on the promise of cell-based medicines, and with Laura at the helm, is well-positioned to make rapid progress towards clinical evaluation.

The companys scientific founders include several of the experts from the University of Pennsylvania who authored two landmark studies establishing preclinical proof-of-concept for non-viral, in vivo CAR-T therapy that Capstan plans to develop and advance toward the clinic. A 2019 Nature publication demonstrated the preclinical use of ex vivo CAR-T cell therapy against FAP, a fibrosis-related target. A follow-on study published in Science earlier this year built on these earlier results and demonstrated the production of functional CAR-T cells in vivo in a mouse model following a single IV administration of an mRNA encoding an anti-FAP CAR packaged in CD5-targeted-LNPs. The scientific founders span diverse areas of research expertise:

Capstan is uniting several recent life science technological advances in a manner that can hopefully unlock the potential of these technologies to develop new medicines for patients across a wider range of diseases, said Drew Weissman, M.D., Ph.D., Co-Founder of Capstan, who serves as the Roberts Family Professor in Vaccine Research and Director of the Penn Institute for RNA Innovation in the Perelman School of Medicine at the University of Pennsylvania, and co-recipient of the 2021 Lasker-DeBakey Clinical Medical Research Award.

Research conducted at Penn demonstrates the tremendous promise of harnessing mRNA and targeted LNP delivery to train a patients body to make CAR-T cells in vivo, potentially creating new treatment options, said Jonathan Epstein, M.D., Chief Scientific Officer at Penns Perelman School of Medicine. We believe this approach has the potential to make an important impact not only in oncology, but also in fibrosis and many other diseases. My fellow scientific co-founders and I all look forward to actively partnering with Capstan in our collaborative effort to develop medicines that may benefit patients around the world.

About Capstan (www.capstantx.com)

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company is co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania. Capstan has a bicoastal presence with operations in San Diego, CA and Philadelphia, PA. For more information, please visit http://www.capstantx.com and follow us on LinkedIn.

University of Pennsylvania Financial Disclosure: The laboratories of Drs. Epstein, Weissman, Pur, Albelda and June have received, or may receive in the future, sponsored research funding from Capstan. Penn, and Drs. Weissman, June, Levine, Epstein, Pur, Albelda, Parhiz and Aghajanian each own equity interests in Capstan. Penn and Drs. Weissman, June, Levine, Epstein, Pur, Albelda, Parhiz and Aghajanian have either received, or may receive in the future, license-related financial consideration related to the licensing of certain Penn intellectual property to Capstan. In their capacity as Penn faculty, Drs. Weissman, Albelda, June and Levine also have existing sponsored research and founding relationships with other commercial entities focused on the research and development of mRNA, LNP, cell therapy or immunotherapy technologies.

Read more:
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering - Business Wire

During the projected period, the market is anticipated to grow as patient preferences shift from traditional medication distribution to the use of enhanced drug administration.

JERSEY CITY, N.J., Sept. 15, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Pharmaceutical Drug Delivery Market" By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery), By Application (Infectious Diseases, Cancer), and By Geography.

According to an extensive study conducted by Verified Industry Research on the Pharmaceutical Drug Delivery Market, the market was valued at USD 1,403.2 Billion in 2021 and is projected to reach USD 2,583 Billion by 2030, growing at a CAGR of 6.6% from 2022 to 2030.

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=7648

Browse in-depth TOC on "Pharmaceutical Drug Delivery Market"

202 - Pages126 Tables37 Figures

Global Pharmaceutical Drug Delivery Market Overview

The processes, formulations, manufacturing procedures, storage arrangements, and technologies utilized to deliver a pharmaceutical substance to its designated therapeutic location are referred to as drug delivery. To increase efficacy and safety, as well as patient convenience and compliance, principles relating to drug production, mode of administration, site-specific targeting, metabolism, and toxicity are applied.

Drug delivery uses a variety of excipients, medicine carriers, and medical devices to modify the pharmacokinetics and specificity of a drug. There is a greater focus on extending a drug's duration of action and bioavailability in order to improve therapeutic outcomes.

Drug delivery is a concept that is closely related to dose form and mode of administration; in fact, the latter is occasionally included in the definition. Despite the fact that the phrases drug delivery and route of administration are sometimes used interchangeably, they are two different ideas. The term "route of administration" refers to the way a medication takes to enter the body, even if "drug delivery" also includes the engineering of delivery systems and may comprise various dosage forms and devices.

Chronic illness incidence is on the rise, the biologics industry is expanding, and new innovative products are being introduced. Ocular inserts, insulin jets, wearables, and other medical devices are being used more often as a result of innovative product debuts that have raised user satisfaction and productivity. The global pharmaceutical delivery market is anticipated to increase as a result of significant investments made by manufacturers in identifying patient requirements and developing products that address those needs.

The Global pharmaceutical drug delivery market has been segmented by Verified Market Research by route of administration, under which the oral drug delivery segment is expected to lead the market. The infectious diseases segment leads the market by application.

Key Developments

Key Players

The major players in the market are Johnson & Johnson, Novartis International AG, F. Hoffmann-La Roche AG, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., Inc., Sanofi, and AbbVie Inc.

Verified Market Research has segmented the Global Pharmaceutical Drug Delivery Market On the basis of Route of Administration, Application, and Geography.

Browse Related Reports:

Insulin Delivery Devices Market By Device Type (Pumps, Pen Needles), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By End-User (Hospitals, Clinics), By Geography, And Forecast

Oxygen Conservation Devices Market By Product (Reservoir Oxygen Delivery Devices, Electromechanical Pulsing Devices), By End-Use (Hospitals And Clinics, Long-Term Care Units), By Geography, And Forecast

Healthcare Nanotechnology (Nanomedicine) Market By Modality (Treatment, Diagnostics), By Indication (Clinical oncology, Infectious diseases), By Application (Drug Delivery, Regenerative medicine), By Geography, And Forecast

Transmucosal Drug Delivery Devices Market By Product (Buccal Route, Rectal Route, Nasal Route), By Application (Hospital, Residential) By Geography, And Forecast

Leading Drone Package Delivery Companies taking off for quick deliveries

Visualize Pharmaceutical Drug Delivery Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact Us

Mr. Edwyne FernandesVerified Market ResearchUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll Free: +1 (800)-782-1768Email: [emailprotected]Web: https://www.verifiedmarketresearch.com/Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1315349/Verified_Market_Research_Logo.jpg

SOURCE Verified Market Research

Read the original:
Pharmaceutical Drug Delivery Market is expected to generate a revenue of USD 2,583 Billion by 2030, Globally, at 6.6% CAGR: Verified Market Research -...

DALLAS Sept. 09, 2022 Childrens Health,one of the largest and most prestigious pediatric health care providers in the country and the leading pediatric health care system in North Texas, today announced that Childrens Health will initiate and create an approximately 100-bed inpatient unit at the new State Psychiatric Hospital for children and adolescents. The adult hospital is being developed through a partnership between UTSouthwestern Medical Center and the Texas Health and Human Services Commission (HHSC). The pediatric unit is in addition to 200 adult beds at the new state hospital, which is currently in the planning stages of design and construction and expected to open in fall 2025 with the pediatric addition scheduled to open in early 2026.

This donation is a key part of our comprehensive strategy and ongoing commitment to expand access to pediatric and adolescent behavioral health services in North Texas, said Lindsey Tyra, Executive Vice President and Chief Strategy Officer at Childrens Health. We know that addressing this growing pediatric mental health crisis requires a concerted, coordinated response from resources and experts across our community. In collaboration with UTSouthwestern through our joint pediatric enterprise, we are building a sweeping and forward-looking approach to this escalating problem that will also be part of a larger statewide system.

According to the Childrens Health 2021 Beyond ABC Report, an estimated 133,375 North Texas children suffer from an emotional disturbance or addictive disorder, and in 2020 alone, there was a 24% increase in mental health-related Emergency Room visits for children ages 5 to 11. By supporting the expansion of inpatient pediatric psychiatric services at the new state hospital, more North Texas children and adolescents through age 17 with complex mental health needs will have access to behavioral health services when they need it most.

Hicham Ibrahim, M.D.

Our goal is to build a state-of-the-art facility that meets the needs of the communities we serve, says Dr. Hicham Ibrahim, Professor of Psychiatry and Associate Vice President and Chief Medical Officer, Ambulatory Services at UTSouthwestern. This donation gives us the opportunity to better address the mental health crisis affecting pediatric patients in our region and provide them with the specialized care they deserve.

This hospital will save lives, and with this donation, thatll include the lives of children as well, said Scott Schalchlin, Deputy Executive Commissioner for the HHSC Health and Specialty Care System. By expanding access to children and adolescents, were helping to address a truly critical need in our communities: taking care of the mental and physical health of our young people.

For updates on the hospitals progress and additional information on how Childrens Health is working with UTSouthwestern and the Texas Health and Human Services Commission, visit State Hospital Construction Projects.

About UTSouthwestern Medical Center

UTSouthwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 26 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in more than 80 specialtiesto more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

About Childrens Health

Childrens Healthis committed to making life better for children. As one of the largest and most prestigious pediatric health care providers in the country and the leading pediatric health care system in North Texas, Childrens Health cares for children through more than 750,000 patient visits annually. The Childrens Health system includes its flagship hospital, Childrens Medical Center Dallas, as well as Childrens Medical Center Plano, the Childrens Health Care Network, specialty centers, rehabilitation facilities and physician services. Childrens Medical Center Dallas continues to be the only North Texas hospital to be ranked in 10 out of 10 pediatric specialties byU.S. News & World Report. Through its academic affiliation with UTSouthwestern Medical Center, Childrens Health is a leader in life-changing treatments, innovative technology and ground-breaking research. This affiliation led to establishing the Childrens Medical Center Research Institute in 2011, committed to pursuing research in regenerative medicine, cancer biology and metabolism. For more information, follow Childrens Health onFacebook,Twitter,Instagram LinkedInYouTube, or visitChildrens.com.

About Texas Health and Human Services

The Texas Health and Human Services Commission owns or operates10 state hospitals, one residential treatment center and 13 state supported living centers across the state. State hospitals provide inpatient psychiatric services to adults, children and adolescents, and state supported living centers serve individuals with intellectual or developmental disabilities. HHSC is also working to serve the growing needs of Texans by modernizing or expanding state hospitals throughout Texas and building a new hospital in Dallas.

Read more:
Children's Health will fund pediatric unit at the Texas Health and Human Services Commission UT Southwestern Medical Center psychiatric hospital - UT...